# A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

> **NCT01648179** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Infections, Bacterial

## Interventions

- **DRUG:** GSK1322322 (mesylate salt) Powder for Injection
- **DRUG:** GSK1322322 (freebase) tablets
- **DRUG:** GSK1322322 (mesylate salt) Powder for Oral Solution
- **DRUG:** GSK1322322 (freebase) tablets FED

## Key facts

- **NCT ID:** NCT01648179
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01648179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01648179, "A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01648179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*